Innovative Research Presented at the San Antonio Breast Cancer Symposium

The Cancer Vaccine Institute (CVI) took park in the 2025 San Antonio Breast Cancer Symposium from December 9-12, 2025, bringing our latest research to one of the world's leading forums for breast cancer science. Faculty members from the CVI presented four scientific posters with fellow collaborators, researchers, and scientists.

Through these presentations, the CVI team highlighted recent discoveries in HER2-targeted vaccines, neoadjuvant immunotherapy, and findings from our long-term clinical trials. We are proud to contribute to the growing body of research shaping the future of breast cancer prevention and treatment.

One poster showcased progress on our HER2-directed vaccine, which may reduce risk of brain metastases in HER2-positive patients. Read more

Another presentation explored how gut bacteria may influence breast cancer growth and treatment response, offering new insights into the role of the microbiome in cancer care. Read more

We shared encouraging results from our WOKVAC vaccine, which lowers breast cancer recurrence rates. Thank you to the Moffitt Cancer Center for leading this important multi-center clinical trial. Read more

In addition, our DNA-based HER2 vaccine resulted in higher immune responses compared to our peptide vaccine, indicating stronger and more comprehensive immune activation. Read more

We are proud of our team for their dedication and for sharing their expertise with the scientific community. We have much to look forward to as we work closer towards a cancer-free future!